Reason for request

Renewal of inclusion on the list of medicines reimbursable by National Health Insurance at the same time as the renewal of inclusion of ZOMETA.

-


Clinical Benefit

Substantial

The transparency Committee considers that actual benefit of ACLASTA remains substantial in all of these indications.


Contact Us

Évaluation des médicaments

See also